Popular pre-market trades in the US stock market: Ryde pre-market down 7.00%; Lam Research pre-market up 3.31%

Pre-market Hot Trades in US Stocks Ryde, down 7.00% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Lam Research up 3.31% in pre-market. Based on recent key news: On December 30, Lam Research's stock performed strongly, mainly due to several financial research institutions raising their target prices, anticipating continued acceleration in demand for its wafer manufacturing equipment in the AI and high-performance computing sectors. Analysts expect its quarterly earnings per share (EPS) to be $1.15, a year-on-year increase of 26%, with quarterly revenue expected to reach $5.22 billion, a year-on-year increase of 19%. Source: Zhitong Finance On December 30, China requires chip manufacturers to ensure that at least 50% of new production capacity is domestic equipment, impacting the market share of foreign companies like Lam Research. This move is one of China's important measures to reduce reliance on foreign technology. Source: Reuters On December 31, analysts pointed out that as the semiconductor industry approaches a trillion-dollar revenue base, AI demand and memory chip manufacturing will enjoy long-term market growth, with Lam Research having advantages in this field. Source: Zacks Investment Research, strong demand in the semiconductor industry, significant policy impact. Top Gainers in Pre-market US Stocks ChowChow Cloud, up 64.46% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Eason Tech, up 37.26% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Ironwood Pharmaceuticals up 35.61% in pre-market. Based on recent key news: On January 2, Ironwood Pharmaceuticals announced that its 2026 revenue outlook exceeds Wall Street expectations. The net sales of its gastrointestinal disease treatment drug Linzess, co-marketed with AbbVie, are expected to rise, driving the stock price up. On January 2, the company expects adjusted EBITDA for 2026 to exceed $300 million, a significant increase from last year. This financial outlook has boosted market confidence, further stimulating the stock price. On January 2, Ironwood Pharmaceuticals met with the FDA and plans to initiate confirmatory trials in the first half of 2026. This move indicates the company's R&D progress in treating short bowel syndrome, boosting investor sentiment. The pharmaceutical industry has performed strongly recently, with significant capital inflows